The 2023 revision of USP 797 (which took effect in November 2023) significantly strengthened requirements, including more rigorous environmental monitoring, tighter beyond-use dating unless additional testing is performed, and enhanced personnel competency requirements
June 17, 2026 *An earlier version of this article, which displayed an incorrect image, has been corrected
Transform Bodies, Transform Lives, Transform Your Business
Our Assessment Process Before starting any GLP-1 medication, the MedBridge team conducts a comprehensive assessment that includes: Reviewing your full medical history and current medications Evaluating for previous episodes of pancreatitis, personal or family history of certain endocrine tumors, and other potential contraindications Screening for pregnancy or breastfeeding, as GLP-1 therapy is not recommended in these cases GLP-1 medications are not intended for those seeking weight loss solely for cosmetic reasons or for patients with certain medical contraindications
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
